Research team identified Neurexin2 as a novel target for
potential therapy of neurodegeneration in Spinal Muscular Atrophy patients
A recent study led by scientists from the National
University of Singapore (NUS) opens a possible new route for treatment of
Spinal Muscular Atrophy (SMA), a devastating disease that is the most common
genetic cause of infant death and also affects young adults. As there is
currently no known cure for SMA, the new discovery gives a strong boost to the
fight against SMA.